Inventor · disambiguated record
Branden Moriarity
Also filed as: MORIARITY BRANDEN · MORIARITY BRANDEN S · MORIARITY BRANDEN SCOTT
21 granted patents·27 pending applications·107 citations·filing 2016–2025
94Inventor score
Files withUNIV MINNESOTA36B MOGEN BIOTECHNOLOGIES INC7INTIMA BIOSCIENCE INC2R&D SYSTEMS INC2MORIARITY BRANDEN S1
Top patents by PatentIndex Score
48 records- 0198US10166255B2Intracellular genomic transplant and methods of therapyUNIV MINNESOTA·Filed 2016·Granted Jan 1, 2019·43 cites·31 claims
- 0296US11266692B2Intracellular genomic transplant and methods of therapyUNIV MINNESOTA·Filed 2020·Granted Mar 8, 2022·3 cites·19 claims
- 0396US11154574B2Tumor infiltrating lymphocytes and methods of therapyUNIV MINNESOTA·Filed 2020·Granted Oct 26, 2021·8 cites·12 claims
- 0496US10406177B2Modified cells and methods of therapyUNIV MINNESOTA·Filed 2016·Granted Sep 10, 2019·18 cites·23 claims
- 0595US11162084B2Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methodsB MOGEN BIOTECHNOLOGIES INC·Filed 2020·Granted Nov 2, 2021·4 cites·18 claims
- 0694US11147837B2Modified cells and methods of therapyUNIV MINNESOTA·Filed 2016·Granted Oct 19, 2021·6 cites·49 claims
- 0792US10912797B2Tumor infiltrating lymphocytes and methods of therapyUNIV MINNESOTA·Filed 2018·Granted Feb 9, 2021·9 cites·33 claims
- 0891US11111483B2Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems and methodsB MOGEN BIOTECHNOLOGIES INC·Filed 2017·Granted Sep 7, 2021·4 cites·24 claims
- 0990US11278570B2Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methodsB MOGEN BIOTECHNOLOGIES INC·Filed 2019·Granted Mar 22, 2022·4 cites·27 claims
- 1087US10227574B2Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methodsB MOGEN BIOTECHNOLOGIES INC·Filed 2018·Granted Mar 12, 2019·5 cites·29 claims
- 1183US10640570B2Chimeric antigen receptors, compositions, and methodsUNIV MINNESOTA·Filed 2016·Granted May 5, 2020·3 cites·7 claims
- 1281US2022362297A1Intracellular genomic transplant and methods of therapyUNIV MINNESOTA·Filed 2022·Application pending·0 cites
- 1380US2022125843A1Modified cells and methods of therapyUNIV MINNESOTA·Filed 2021·Application pending·0 cites
- 1477US12037611B2Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methodsR&D SYSTEMS INC·Filed 2021·Granted Jul 16, 2024·0 cites·19 claims
- 1576US11903966B2Intracellular genomic transplant and methods of therapyUNIV MINNESOTA·Filed 2018·Granted Feb 20, 2024·0 cites·46 claims
- 1676US11642375B2Intracellular genomic transplant and methods of therapyUNIV MINNESOTA·Filed 2018·Granted May 9, 2023·0 cites·31 claims
- 1776US11642374B2Intracellular genomic transplant and methods of therapyUNIV MINNESOTA·Filed 2018·Granted May 9, 2023·0 cites·17 claims
- 1876US11583556B2Modified cells and methods of therapyUNIV MINNESOTA·Filed 2020·Granted Feb 21, 2023·0 cites·8 claims
- 1976US2024294664A1Chimeric antigen receptors, compositions, and methodsUNIV MINNESOTA·Filed 2024·Application pending·0 cites
- 2075US11925664B2Intracellular genomic transplant and methods of therapyUNIV MINNESOTA·Filed 2020·Granted Mar 12, 2024·0 cites·25 claims
- 2173US2022105133A1Tumor infiltrating lymphocytes and methods of therapyUNIV MINNESOTA·Filed 2021·Application pending·0 cites
- 2272US12097220B2Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methodsR&D SYSTEMS INC·Filed 2022·Granted Sep 24, 2024·0 cites·20 claims
- 2367US2025197826A1Genetically engineered t cell for cell therapyUNIV MINNESOTA·Filed 2023·Application pending·0 cites
- 2467US2020330517A1Tumor infiltrating lymphocytes and methods of therapyUNIV MINNESOTA·Filed 2020·Application pending·0 cites
- 2566US2023399618A1Methods, compositions, and kits for expanding natural killer cellsUNIV MINNESOTA·Filed 2022·Application pending·0 cites
- 2666US2025017966A1Large-scale expansion of engineered human gamma delta t cellsUNIV MINNESOTA·Filed 2022·Application pending·0 cites
- 2765US2025049850A1Non-viral b cell engineering methodsUNIV MINNESOTA·Filed 2022·Application pending·0 cites
- 2864US12030953B2Chimeric antigen receptors, compositions, and methodsUNIV MINNESOTA·Filed 2020·Granted Jul 9, 2024·0 cites·11 claims
- 2962US2022282285A1Genetically-edited immune cells and methods of therapyUNIV MINNESOTA·Filed 2022·Application pending·0 cites
- 3062US2025242023A1Genetically engineered t cell receptorsUNIV MINNESOTA·Filed 2022·Application pending·0 cites
- 3161US11760983B2Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methodsB MOGEN BIOTECHNOLOGIES INC·Filed 2019·Granted Sep 19, 2023·0 cites·23 claims
- 3260US2018245055A1Enhanced hAT Family Transposon-Mediated Gene Transfer and Associated Compositions, Systems, and MethodsB MOGEN BIOTECHNOLOGIES INC·Filed 2018·Application pending·0 cites
- 3359US2024042029A1Delivery of molecules to cells using trogocytosis and engineered cellsUNIV MINNESOTA·Filed 2021·Application pending·0 cites
- 3454US2023272355A1ENHANCED hAT FAMILY MEMBER SPIN TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODSB MOGEN BIOTECHNOLOGIES INC·Filed 2021·Application pending·0 cites
- 3553US12281327B2Lymphohematopoietic engineering using CAS9 base editorsUNIV MINNESOTA·Filed 2019·Granted Apr 22, 2025·0 cites·7 claims
- 3653US2024352420A1Multiplex base editing of primary human natural killer cellsUNIV MINNESOTA·Filed 2022·Application pending·0 cites
- 3752US2025290101A1Lymphohematopoietic engineering using cas9 base editorsUNIV MINNESOTA·Filed 2025·Application pending·0 cites
- 3851US2021254068A1Genome engineering primary monocytesUNIV MINNESOTA·Filed 2019·Application pending·0 cites
- 3951US2024026292A1Engineered immune cells for reagent deliveryUNIV MINNESOTA·Filed 2021·Application pending·0 cites
- 4050US2024101993A1Enhancing efficiency of targeted gene knockin by base editorsUNIV MINNESOTA·Filed 2022·Application pending·0 cites
- 4146US2022168342A1Genome edited primary b cell and methods of making and usingUNIV MINNESOTA·Filed 2017·Application pending·0 cites
- 4245US2022002717A1Programmable nucleases and base editors for modifying nucleic acid duplexesUNIV MINNESOTA·Filed 2019·Application pending·0 cites
- 4345US2022088074A1Genetically modified gamma delta t cells and methods of making and usingUNIV MINNESOTA·Filed 2020·Application pending·0 cites
- 4444US2019374576A1Viral methods of t cell therapyINTIMA BIOSCIENCE INC·Filed 2019·Application pending·0 cites
- 4543US2019382799A1Viral methods of making genetically modified cellsINTIMA BIOSCIENCE INC·Filed 2019·Application pending·0 cites
- 4643US2017298391A1Conditional rescue system, cells, and methodsUNIV MINNESOTA·Filed 2017·Application pending·0 cites
- 4742US2019038780A1Vectors and system for modulating gene expressionUNIV MINNESOTA·Filed 2017·Application pending·0 cites
- 4834US2020208111A1Genome-edited nk cell and methods of making and usingMORIARITY BRANDEN S·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Branden Moriarity files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →